Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC

Lung Cancer. 2014 May;84(2):203-5. doi: 10.1016/j.lungcan.2014.02.010. Epub 2014 Feb 28.

Abstract

Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib.

Keywords: Acquired resistance; Chemotherapy; EGFR-TKI; NSCLC; Pemetrexed; Rechallenge.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / secondary
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride
  • Glutamates / administration & dosage
  • Guanine / administration & dosage
  • Guanine / analogs & derivatives
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Mutation, Missense
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / prevention & control
  • Pemetrexed
  • Quinazolines / administration & dosage
  • Radiography
  • Treatment Outcome

Substances

  • Glutamates
  • Quinazolines
  • Pemetrexed
  • Guanine
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors